IP Library Granted Patent US 12668621
Granted Patent B2
US 12668621 · App. 17/627,167 · Granted Jun 30, 2026

Compositions and methods for the treatment of tuberculosis

Inventors: Natalia Freund (Tel-Aviv, IL); Ronen Weiss (Tel-Aviv, IL)
Assignee: Ramot at Tel-Aviv University Ltd.
C07K16/1289A61P31/06C12N1/20C12N15/70C12P21/005G01N33/5695C07K2317/21C12N2800/101
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12668621
App. No.
17/627,167
Granted
Jun 30, 2026
Kind
B2
Abstract

A human antibody comprising an antigen binding domain which binds PstS1 of Mycobacterium tuberculosis (TB) for use in preventing or treating TB infection in a subject in need thereof is provided. Also provided are vaccine compositions and conjugates of such antibodies.

Claims (10)

1 . A method of preventing or treating Mycobacterium tuberculosis (TB) in a subject in need thereof, the method comprising administering to the subject an effective amount of an antibody capable of binding Psts1 of TB, wherein said antibody is selected from the group consisting of:

(i) an antibody comprising CDRH1 comprising SEQ ID NO: 2, CDRH2 comprising SEQ ID NO: 3, CDRH3 comprising SEQ ID NO: 4, CDRL1 comprising SEQ ID NO: 6, CDRL2 comprising SEQ ID NO: 7 and CDRL3 comprising SEQ ID NO: 8;

(ii) an antibody comprising CDRH1 comprising SEQ ID NO: 10, CDRH2 comprising SEQ ID NO: 11, CDRH3 comprising SEQ ID NO: 12, CDRL1 comprising SEQ ID NO: 14, CDRL2 comprising SEQ ID NO: 15 and CDRL3 comprising SEQ ID NO: 16;

(iii) an antibody comprising CDRH1 comprising SEQ ID NO: 18, CDRH2 comprising SEQ ID NO: 19, CDRH3 comprising SEQ ID NO: 20, CDRL1 comprising SEQ ID NO: 22, CDRL2 comprising SEQ ID NO: 23 and CDRL3 comprising SEQ ID NO: 24;

(iv) an antibody comprising CDRH1 comprising SEQ ID NO: 26, CDRH2 comprising SEQ ID NO: 27, CDRH3 comprising SEQ ID NO: 28, CDRL1 comprising SEQ ID NO: 30, CDRL2 comprising SEQ ID NO: 31 and CDRL3 comprising SEQ ID NO: 32;

(v) an antibody comprising CDRH1 comprising SEQ ID NO: 34, CDRH2 comprising SEQ ID NO: 35, CDRH3 comprising SEQ ID NO: 36, CDRL1 comprising SEQ ID NO: 38, CDRL2 comprising SEQ ID NO: 39 and CDRL3 comprising SEQ ID NO: 40;

(vi) an antibody comprising CDRH1 comprising SEQ ID NO: 42, CDRH2 comprising SEQ ID NO: 43, CDRH3 comprising SEQ ID NO: 44, CDRL1 comprising SEQ ID NO: 46, CDRL2 comprising SEQ ID NO: 47 and CDRL3 comprising SEQ ID NO: 48;

(vii) an antibody comprising CDRH1 comprising SEQ ID NO: 50, CDRH2 comprising SEQ ID NO: 51, CDRH3 comprising SEQ ID NO: 52, CDRL1 comprising SEQ ID NO: 54, CDRL2 comprising SEQ ID NO: 55 and CDRL3 comprising SEQ ID NO: 56; and

viii) an antibody comprising CDRH1 comprising SEQ ID NO: 58, CDRH2 comprising SEQ ID NO: 59, CDRH3 comprising SEQ ID NO: 60, CDRL1 comprising SEQ ID NO: 62, CDRL2 comprising SEQ ID NO: 63 and CDRL3 comprising SEQ ID NO: 64,

wherein said CDRH1, CDRH2, CDRH3 are arranged from N to C on the heavy chain of said antibody and CDRL1, CDRL2 and CDRL3 are arranged from N to C on the light chain of said antibody, thereby preventing or treating TB in the subject.